Taken together, these data suggest that: (i) even though breast cancer cells possess low ZNF217 levels, knock-down of ZNF217 endogenous protein expression dramatically affects their proliferation (Figures 3C and 3F); (ii) the negative regulation of cell proliferation observed with decreased levels of ZNF217 is exerted in a dose-dependent manner (Figure 3F). Here, ZNF217 is linked to breast carcinoma.